Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial

Senti Biosciences Inc. (Nasdaq: SNTI) recently said that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the company’s investigational, off-the-shelf logic-gated CAR-NK therapy for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The designation follows an Orphan Drug label in June 2025 and was announced alongside Phase-1 data presented at the American Society of Hematology (ASH) showing a 50% overall response rate (ORR) and a 42% complete remission (CR/CRh) rate at the recommended Phase-2 dose (RP2D).

Deep Remissions in A Small, Heavily Pretreated Cohort

Updated results from the ongoing multinational Phase-1 trial (NCT06325748) — 20 patients enrolled, 18 evaluable — showed a 42% complete remission rate at the recommended Phase 2 dose. Every complete remission tested negative for measurable residual disease (MRD). A Kaplan-Meier estimate placed the median duration of remission at 7.6 months. These results suggest the therapy offers meaningful durability in a heavily pretreated patient population.

The safety profile showed no dose-limiting toxicities related to the therapy. No treatment-related serious adverse events appeared in the dataset. Most adverse events were Grade 1–2 pyrexia, characterized as delayed infusion-related reactions. This profile could support outpatient delivery if confirmed in larger cohorts.

“SENTI-202 continues to demonstrate deep, durable responses and a favorable safety profile in patients with relapsed or refractory AML, where standard therapies often offer patients a survival rate of just a few months,” said Nosha Farhadfar, M.D., lead investigator on the trial. “I’m looking forward to continuing to participate in this clinical evaluation to further investigate SENTI-202’s efficacy and safety.”

How the Gene Circuit Works: Or/Not Logic and Engineered Persistence

SENTI-202 is a cell therapy developed using Senti’s Gene Circuit platform. It is designed to target acute myeloid leukemia (AML) while minimizing damage to healthy blood cells. The therapy combines three engineered components:

1. Activating OR gate: This recognizes two leukemia markers, CD33 and FLT3, to direct the therapy specifically against cancer cells.
2. Inhibitory NOT gate: This detects EMCN, a marker on healthy blood stem cells (HSPCs), and prevents the therapy from attacking normal bone marrow.
3. Calibrated-release IL-15 module: This releases a small amount of IL-15, a molecule that supports immune cell growth, helping the infused natural killer (NK) cells persist and remain active in the body.

SENTI-202 uses donor-derived NK cells that are manufactured, frozen, and stored, making the therapy “off-the-shelf” and ready for use without needing a patient-specific preparation.

Early company data reported that after infusion, the NK cells expanded in the patient’s blood during the first two weeks, then naturally decreased over time. This behavior is consistent with what has been observed in other allogeneic (donor-derived) NK cell therapies.

“To overcome this longstanding key challenge, our Logic Gated cell therapies recognize and kill cancer cells based on multiple targets while simultaneously protecting healthy cells from toxicity,” said Timothy Lu, M.D., Ph.D., co-founder and CEO of Senti Biosciences.

Market Analysis: Regulatory Validation Meets Financial Reality

The stock experienced extreme volatility following the announcement, despite the regulatory milestone. The FDA’s decision to grant RMAT designation to SENTI-202 strategically positions Senti Biosciences within the AML landscape. This regulatory milestone provides a competitive advantage by enabling more intensive FDA guidance and the potential for rolling review. For a clinical-stage company, RMAT status reduces regulatory risk and may accelerate the timeline to potential commercialization. It signals to the market that the agency views the “Logic Gated” technology as a viable solution to the toxicity issues that have historically challenged AML cell therapies.

Despite this long-term validation, the immediate market reaction highlights a sharp disconnect between clinical progress and financial durability. Shares fluctuated sharply, with a peak gain of 47.4% and a trough of 50.4%, before ultimately closing down 35.6%, erasing roughly $35 million in market capitalization. Trading volume surged to more than 600 times the daily average, and momentum scanners registered 100 alerts during the session, indicating heightened investor activity. This reaction reflects investor focus on the company’s broader financial picture rather than the science alone.

Senti Bio reported an $18.1 million net loss in its most recent quarter and disclosed limited cash reserves leading into the ASH conference. The market appears to be weighing clinical efficacy against the capital-intensive task of advancing pivotal trials. Positive clinical data, while validating, also accentuates near-term funding needs, and investors may be anticipating a potential financing event to support the accelerated development pathway enabled by RMAT.

Financial Pressure Highlights Need for Differentiation and Scalability in a Competitive Allogeneic NK Landscape

This financial context creates a “prove-it” dynamic for the company’s operational execution in the coming months. Senti Bio must differentiate itself not only through clinical data but also through scalability. The “off-the-shelf” CAR-NK model offers potential cost advantages over autologous therapies, which require patient-specific manufacturing. Competitors such as Fate Therapeutics and Nkarta are also actively developing allogeneic NK therapies, making differentiation crucial. Senti’s proprietary “OR/NOT” circuit remains a key advantage, potentially expanding the addressable market by treating patients who cannot tolerate the off-target toxicity of other drugs. The RMAT designation serves as a notable endorsement of this differentiated mechanism, potentially increasing Senti’s attractiveness as a partner for larger pharmaceutical companies seeking de-risked oncology assets.

However, competitors like Fate Therapeutics and Nkarta are also racing to define standards in this allogeneic space. Senti’s proprietary “OR/NOT” circuit remains its key differentiator, potentially opening a larger addressable market by treating patients who cannot tolerate the off-target toxicity of rival drugs. The RMAT designation serves as a crucial endorsement of this differentiated mechanism, potentially making Senti a more attractive partner for larger pharmaceutical companies seeking de-risked assets in oncology.

Strategic Implications and Future Outlook

The FDA’s RMAT designation underscores the urgent need for new solutions in relapsed/refractory AML, where median survival is typically measured in months. This status enables frequent regulatory interaction and potential rolling review, accelerating development for a condition that historically lacks cancer-specific antigens. Senti Bio positions SENTI-202 as the lead validation of its modular Gene Circuit platform, intended for broader deployment across both NK and T cell modalities. “This clinical evidence allows us to rapidly advance SENTI-202 into pivotal studies,” said Chief Medical Officer Dr. Kanya Rajangam.

However, the transition from proof-of-concept to routine clinical use faces significant hurdles. The current dataset remains small with limited follow-up, leaving open questions regarding long-term durability and safety in diverse cohorts. Operational success will depend on scaling manufacturing for the allogeneic product and ensuring supply chain consistency. Investors and clinicians will closely monitor forthcoming pivotal trial designs to see if the company can replicate these initial results in a larger population.

Author

Bernice Lottering